Compare Moderna, Inc. (MRNA) vs T-Mobile Us Inc (TMUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Moderna, Inc. vs T-Mobile Us Inc — how do they compare? Moderna, Inc. trades at $137.48 (market cap $56.02B), while T-Mobile Us Inc trades at $177.96 (market cap $194.89B). The key difference: T-Mobile Us Inc is far larger — about 3.5× Moderna, Inc.'s market cap, and T-Mobile Us Inc pays a 2.25% dividend while Moderna, Inc. pays none. Which is the better fit depends on your goals.
| MRNA | TMUS | |
|---|---|---|
Market Cap | $56.02B | $194.89B |
Sector | Health | Media |
52-Week High | $174.38 | $241.67 |
52-Week Low | $22.36 | $167.65 |
Enterprise Value | $52.17B | $311.51B |
Dividend Yield | — | 2.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Moderna (MRNA) trades at $140.33, down 3.59% on the day, amid mixed signals. The stock has seen volatility, with a 143% surge over the past month driven by positive cancer vaccine trial results (Fox Business, 2026-09-06), but faces headwinds from declining revenue and persistent net losses. Technical analysis shows a bullish overall signal, with support at $138 and resistance at $145, while fundamentals reveal a challenging profit margin of -142.58% for 2026.
The outlook hinges on pipeline successes, particularly in oncology, but high valuation ratios and competitive pressures pose risks. Analyst consensus is cautious, with a $90.08 price target, reflecting skepticism despite recent clinical milestones. Investors should weigh innovation potential against financial sustainability and market sentiment shifts.
T-Mobile US (TMUS) trades at $181.69, showing minimal daily movement (+0.09%) amid a bearish technical signal. The company demonstrates strong fundamentals with $88.3B revenue (2025) and consistent earnings beats in recent quarters. Analyst sentiment remains overwhelmingly positive with 80% buy ratings and a $233.20 consensus target, though technical indicators show near-term resistance at $183. Recent developments include CFO transition planning and institutional accumulation by California State Teachers Retirement System.
TMUS presents a compelling growth story with solid profitability metrics and analyst support, though technical weakness and competitive pressures warrant caution. The stock's 28% upside to consensus target offers potential, but investors must weigh strong cash flow generation against rising debt levels and sector-wide pricing pressures evident in recent broadband repricing trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Moderna, Inc.
Moderna, Inc. operates as a clinical stage biotechnology company. The Company focuses on the discovery and development of messenger RNA (mRNA) therapeutics and vaccines. Moderna develops mRNA medicines for infectious, immuno-oncology, and cardiovascular diseases.
Read more on MRNA →About T-Mobile Us Inc
Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →
